<DOC>
	<DOCNO>NCT00356590</DOCNO>
	<brief_summary>This open label , multicenter study extend treatment patient participate Immunex clinical study 016.0012 . The primary objective study evaluate long term safety etanercept ( TNFR : Fc ) patient early stage rheumatoid arthritis .</brief_summary>
	<brief_title>Open-Label Extension Treatment With Etanercept ( TNFR : Fc ) Participating Patients Etanercept ( TNFR : Fc ) Clinical Trial 016.0012</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Previous enrollment Immunex protocol 016.0012 . No clinically significant adverse event think due etanercept ( TNFR : Fc ) previous treatment . Negative serum pregnancy test 14 day first dose study drug female childbearing potential . No one NSAID dose great maximum recommend dose stable least two week prior administration etanercept ( TNFR : Fc ) . Previous receipt etanercept ( TNFR : Fc ) ( p55 ) , antibody TNF , antiCD4 antibody , diphtheria IL2 fusion protein . Receipt investigational drug biologics ( etanercept ( TNFR : Fc ) ) within interval study drug 016.0012 study . Receipt DMARDs ( e.g. , hydroxychloroquine , oral injectable gold , azathioprine , cyclosporin , Dpenicillamine , sulfasalazine , minocycline , leflunomide ) MTX within two week prior first dose etanercept ( TNFR : Fc ) study . Receipt cyclophosphamide within 1 month prior first dose etanercept ( TNFR : Fc ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Long-term Safety</keyword>
	<keyword>Enbrel</keyword>
</DOC>